New Atlas

New approach shields memory from brain cancer radiotherapy

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...
Labroots

Study Explores Role of Cannabinoid Receptor Type 2 Activity in Granulocyte Colony-Stimulating Factor (G-CSF) Treatment for Traumatic Brain Injury (TBI)

A study published in the Journal of Cannabis Research examined the effect of granulocyte colony-stimulating factor (G-CSF) on brain recovery following trau | Cannabis Sciences ...
The American Journal of Managed Care

First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA

Concizumab-mtci (Alhemo) is approved for hemophilia A or B with inhibitors, offering a subcutaneous alternative to intravenous treatments. The phase 3 explorer7 trial demonstrated an 86% reduction in ...
McKnight's Long-Term Care News

FDA OKs subcutaneous lecanemab injection for maintenance dosing for early Alzheimer’s

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...
Medscape

FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications

The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as a subcutaneous injection in adults, covering all approved indications ...